Goldfinch Bio Inc.

Plus: Reilly named CEO at Damona, and updates from Akebia, Generate, Jasper and more

Biotech struck by a wave of downsizing, restructuring and closures, as companies run out of options in an unforgiving market

Plus Karuna licenses Goldfinch assets and updates from Vera, BioNTech, Ratio and more

Plus: FDA approves Jaypirca, Lilly’s non-covalent Btk inhibitor and updates from Novartis, Legend, Goldfinch Bio and Relive

Plus Huang becomes Zai CSO and updates from Aadi, VectorY, Fulcrum and Xenon

Plus Raineri becomes CTO at Aspen, and updates from Evozyne, Nabsys, AnHeart and IDSA

BioCentury’s roundup of translational news

Plus Crinetics recruits a chief business officer and updates from Ribometrix and Osler

Plus Kush, Haddach join RayzeBio and updates from Coherus, InterVenn, AsherBio and more

Plus Clyburn leaving Merck & Co. and updates from Third Rock, BioTheryX, Ambys and more